Opioid-use Disorder Clinical Trial
Official title:
Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation
Despite the demonstrated effectiveness of agonist treatment for opioid dependence and alarming recent increases in overdose deaths, waiting lists for treatment persist. In a Behavioral & Integrative Treatment Development pilot study, the investigators demonstrated the initial efficacy a novel Interim Buprenorphine Treatment (IBT) to mitigate the risks (e.g., illicit opioid use, IV drug use) associated with treatment delays. However, consistent with that R34 mechanism, our initial pilot study involved a limited sample size and was conducted at a single academic, well-controlled research clinic with an extensive history of research. It is important to replicate these very positive pilot results and begin to evaluate whether they generalize to less-controlled rural environments that are being so adversely impacted by the current opioid abuse epidemic. In this Stage II randomized parallel two-group trial, the investigators will evaluate the efficacy of IBT using a larger sample of 100 waitlisted opioid-dependent adults (50 IBT, 50 WLC). UVM will serve as the coordinating center and we will aim to partner with health centers and other convenience sites in rural Vermont counties to conduct study visits while overcoming barriers commonly encountered in rural areas (e.g., transportation issues, socioeconomic barriers). The proposed research builds directly on the promising Stage I results and has the potential to substantially reduce the vast individual and societal costs associated with opioid treatment delays.
Despite the demonstrated effectiveness of agonist treatment for opioid dependence and
alarming recent increases in overdose deaths, waiting lists for treatment persist.
Opioid-dependent individuals can remain on waitlists for months, during which they are at
substantial risk for illicit drug use, criminal activity, infectious disease, overdose and
premature death. One effort to reduce these risks has been to extend interim methadone
treatment (IMT; i.e., daily methadone without counseling) to individuals awaiting entry into
a methadone program. IMT significantly reduces illicit opioid use and criminality during
treatment delays. However, it is limited to licensed specialty clinics, requires daily
visits, prohibits take-home doses and cannot exceed a 120-day duration. These regulatory
restrictions have constrained the widespread use of IMT.
With a Behavioral & Integrative Treatment Development R34, the investigators have developed a
novel Interim Buprenorphine Treatment (IBT) to mitigate the risks associated with treatment
delays while surmounting the limitations noted above for methadone. It includes key
components to permit delivery of potentially life-saving pharmacotherapy while minimizing
nonadherence: (a) Buprenorphine (BUP) offers a regulatory and safety profile that is uniquely
compatible with interim dosing. Participants receive BUP maintenance with bi-monthly clinic
visits and the remaining doses dispensed at home via a secure computerized portable device
(Med-O-Wheel, Addoz, Finland). Participants also receive (b) nightly calls from an automated
Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving,
(c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis
education delivered via iPad.
Our Stage I pilot data strongly support the initial efficacy of this intervention. Among 50
waitlisted opioid-dependent adults randomized to IBT (n=25) or Waitlist Control (WLC; n=25)
conditions for 12 weeks, 85%, 84% and 68% of IBT participants are abstinent at 4, 8 and
12-week assessments vs. 0%, 0% and 0% of WLC participants (p<.001). IBT participants also
reported significantly greater reductions in illicit opioid use and IV drug use frequency and
completing 96% of daily IVR calls and random call-backs. These outcomes represented a
substantial first step towards the development of an intervention that can reduce individual
and societal risks during delays to conventional treatment.
However, consistent with the R34 mechanism, our initial pilot study involved a limited sample
size and was conducted at a single academic, well-controlled research clinic with an
extensive history of research and a brief treatment duration. It is important to replicate
these very positive pilot results and begin to evaluate whether they generalize to
less-controlled rural environments that are being so adversely impacted by the current opioid
abuse epidemic as well as over longer treatment durations. Important to underscore is that
our IBT components (i.e., Med-O-Wheel, IVR, HIV+Hepatitis application) are highly
transportable, which increases the potential of extending them to sites outside of the
university setting while retaining efficacy.
Primary Aim: In this Stage II randomized parallel two-group trial, the investigators will
evaluate the efficacy of IBT using a larger sample of 100 waitlisted opioid-dependent adults
(50 IBT, 50 WLC). UVM will serve as the coordinating center and we will aim to partner with
health centers and other convenience sites in rural Vermont counties to conduct study visits
while overcoming barriers commonly encountered in rural areas (e.g., transportation issues,
socioeconomic barriers). Participants randomized to IBT will receive the intervention
described above for a duration of 24-weeks; WLC participants will remain on the waitlist for
their treatment of choice but complete monthly assessments. It is hypothesized that IBT
participants will achieve significantly greater illicit opioid abstinence relative to WLC
participants.
The proposed research builds directly on the promising Stage I results and has the potential
to substantially reduce the vast individual and societal costs associated with opioid
treatment delays. By facilitating the eradication of waitlists, this project represents a
significant departure from the status quo and stands to produce a fundamental shift in how
treatment for opioid dependence is conceptualized and delivered.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04157062 -
An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder
|
N/A | |
Enrolling by invitation |
NCT04527926 -
STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy
|
N/A | |
Completed |
NCT04505540 -
Start Treatment and Recovery for Opioid Use Disorder
|
N/A | |
Completed |
NCT03065049 -
Transforming Recovery Through Exercise and Community
|
N/A | |
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Suspended |
NCT05001789 -
Cognitive Functioning in Opioid Use Disorder
|
N/A | |
Active, not recruiting |
NCT04650386 -
Examining an Adaptive Approach to Providing Psychosocial Support to Buprenorphine Patients
|
N/A | |
Completed |
NCT03715634 -
Study of a Novel Subcutaneous Depot Formulation of Buprenorphine
|
Phase 1 | |
Enrolling by invitation |
NCT04991974 -
Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT04122755 -
Single Ascending Dose Study of ALA-1000
|
Phase 1 | |
Recruiting |
NCT05028998 -
COVID-19-Related Opioid Treatment Policy Evaluation
|
||
Recruiting |
NCT05049460 -
Adjunctive Transcranial Stimulation to Reduce Impulsivity in Opiate Use Disorder
|
N/A | |
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT05047627 -
Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
|
N/A | |
Active, not recruiting |
NCT04129580 -
reSET-O RCT (Randomized Controlled Trial)
|
N/A | |
Recruiting |
NCT03923374 -
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
|
||
Completed |
NCT04056182 -
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
|
Phase 2 | |
Suspended |
NCT02687360 -
Imaging the Effects of rTMS on Chronic Pain
|
N/A | |
Completed |
NCT03766893 -
Medication Maintenance Therapy in Community Pharmacy Settings
|
Early Phase 1 |